Association of Breast Cancer in Men with Exposure to 5-Alpha Reductase Inhibitors: A RADAR Report

May 2012 in “ Journal of Clinical Oncology ”

Steven M. Belknap, Victoria Godinez-Puig, Robert E. Brannigan, Simon Lin, John Cashy, Rajesh Chowdhary, Michael Postelnick, Michael A. Fotis, Michael S. Irwig, Seema A. Khan, William J. Gradishar, Vishvas Garg, Xian Shen, Dennis W. Raisch, Beatrice Nardone, Steven T. Rosen, Beatrice J. Edwards, June M. McKoy, Paul R. Yarnold, Dennis P. West

Studysummary This study found a significant association between male breast cancers and exposure to finasteride and dutasteride, with an estimated additional case per 564 men taking these drugs. Our plain-language summary of this paper — not a Tressless recommendation.

We don't know much about this study yet.

View this study on ascopubs.org →

Discuss this study in the Community →

Related Community Posts Join

6 / 1000+ results

community Is there a correlation between side effect occurence for alpha blockers and alpha reductase inhibitors?

9 years ago

community Duasteride and breast tissue accumulation.

4 upvotes 6 months ago

The user is experiencing breast tissue growth from taking dutasteride and minoxidil, and is considering reducing the dosage or stopping the medication. Suggestions include seeing an endocrinologist, using Raloxifene or Arimidex, and considering topical treatments or surgery if necessary.

community A systematic bro-science review of DHT, 5AR, neurosteroids, sexual health and 5AR inhibitors

37 upvotes 3 years ago

Hair loss treatments, specifically 5AR inhibitors, can impact neurosteroids and sexual health. The effects of topical fin/dut on tissue-specific DHT levels are unclear.

community FCE 28260: A Forgotten 5α-Reductase Inhibitor

in Research 330 upvotes 2 years ago

FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

community Adrogens and Covid-19

8 upvotes 6 years ago

The possible increased risk of severe Covid-19 cases in men due to higher androgen levels, and how taking medications such as finasteride, dutasteride, spironolactone, enzalutamide, or canabidiol might help mitigate the severity of the disease.

community Risk of Saw Palmetto or Propecia increasing male breast size?

11 years ago

Related Research

9 / 9 results

research Evaluation of the Therapeutic Effects of AGA Drugs by Measuring Finasteride, Dutasteride, and Dihydrotestosterone in Hair

June 2023 in “Clinica Chimica Acta”

This study observed that both finasteride and dutasteride significantly decreased dihydrotestosterone concentrations in hair, with dutasteride showing the greatest reduction.

research Change in Hair Growth-Related Gene Expression Profile in Human Isolated Hair Follicles Induced by 5-Alpha Reductase Inhibitors – Dutasteride and Finasteride – in the Presence of Testosterone

1 citations , June 2021 in “Singapore Medical Journal”

This study suggests that type I 5-alpha reductase may also play a role in hair growth, with dutasteride potentially being more potent than finasteride in modulating key hair growth gene expressions.

research 5-Alpha Reductase Inhibitors in Androgenetic Alopecia: Shifting Paradigms, Current Concepts, Comparative Efficacy, and Safety

19 citations , April 2020 in “Dermatologic Therapy”

This review found that dutasteride is more potent than finasteride as a dual receptor dihydrotestosterone blocker for treating androgenetic alopecia and shares a similar safety profile in terms of fertility, teratogenicity, neurotoxicity, and hepatotoxicity.

research Luncheon Symposium: Update on the Efficacy and Safety of Dutasteride in the Management of Androgenetic Alopecia

January 2015 in “프로그램북(구 초록집)”

This article reviews the impact of dutasteride on hair growth in androgenetic alopecia, finding it significantly increases hair count and width compared to finasteride and placebo, but reports no new results.

research Comparison of Clinical Efficacy of Finasteride and Dutasteride as 5-Alpha Reductase Inhibitors

1 citations , January 2012 in “Daehan namseong gwahag hoeji”

This study found that dutasteride was more effective than finasteride in reducing total prostate volume and PSA levels and improving symptoms in patients with benign prostate hyperplasia.

research An Overview on 5α-Reductase Inhibitors

219 citations , October 2009 in “Steroids”

5α-reductase inhibitors, like Finasteride and Dutasteride, help manage benign prostatic hyperplasia.

The Importance of Dual 5α-Reductase Inhibition in the Treatment of Male Pattern Hair Loss: Results of a Randomized Placebo-Controlled Study of Dutasteride Versus Finasteride

research The Importance of Dual 5α-Reductase Inhibition in the Treatment of Male Pattern Hair Loss: Results of a Randomized Placebo-Controlled Study of Dutasteride Versus Finasteride

215 citations , November 2006 in “Journal of The American Academy of Dermatology”

This study found that dutasteride increased scalp hair growth in men with male pattern hair loss, particularly at a 2.5 mg dose, and was more effective than finasteride over 24 weeks.

research The Benefits of Dual Inhibition of 5α Reductase

4 citations , September 2006 in “European Urology Supplements”

Dutasteride reduces DHT and improves BPH symptoms more effectively than finasteride.

research Effective Treatment of Female Androgenic Alopecia with Dutasteride

33 citations , October 2005 in “PubMed”

In this case study, significant improvement in androgenic alopecia was observed in a 46-year-old woman after 9 months of treatment with dutasteride following limited success with finasteride.